<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105270</url>
  </required_header>
  <id_info>
    <org_study_id>2019LS010</org_study_id>
    <nct_id>NCT04105270</nct_id>
  </id_info>
  <brief_title>RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial</brief_title>
  <official_title>A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral&#xD;
      restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab&#xD;
      (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic&#xD;
      adenocarcinoma non-small cell lung cancer (NSCLC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing Progression Free Survival (PFS)</measure>
    <time_frame>3 Years</time_frame>
    <description>Incidence of PFS using RECIST 1.1 in each treatment arm to evaluate the efficacy of restorative microbiota therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of RMT</measure>
    <time_frame>2 Years</time_frame>
    <description>Safety and tolerability of RMT in combination with durvalumab or durvalumab + chemotherapy as assessed by the incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) RECIST 1.1</measure>
    <time_frame>2 Years</time_frame>
    <description>ORR of treatment with RMT in each treatment arm per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>2 Years</time_frame>
    <description>DOR of treatment with RMT in each treatment arm per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 Years</time_frame>
    <description>Incidence of OS using RECIST 1.1 in each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune mediated Adverse Events imAE</measure>
    <time_frame>2 Years</time_frame>
    <description>Rate of immune mediated adverse events (imAE) in each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (iRECIST)</measure>
    <time_frame>2 Years</time_frame>
    <description>ORR using immune response evaluation criteria in solid tumors (iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>2 Years</time_frame>
    <description>Difference in health-related quality of life (QoL) using European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ-30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>2 Years</time_frame>
    <description>Difference in health-related quality of life (QoL) using lung cancer module (LC-13)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Adenocarcinoma of Lung</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (RMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Run-in</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients are enrolled in this safety run-in arm. Patients are directly assigned to RMT treatment arm. After safety- run-in period of 4 weeks after the first dose of RMT, in the 10 patients if no new safety signal are seen enrollment moves to randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Restorative Microbiota Therapy (RMT) Capsules</intervention_name>
    <description>Patients with PD-L1 TC expression will receive sixteen doses of oral RMT capsules weekly</description>
    <arm_group_label>Arm A (RMT)</arm_group_label>
    <arm_group_label>Safety Run-in</arm_group_label>
    <other_name>RMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab 1500 mg IV</intervention_name>
    <description>Patients with PD-L1 TC expression receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab</description>
    <arm_group_label>Arm A (RMT)</arm_group_label>
    <arm_group_label>Arm B (Placebo)</arm_group_label>
    <arm_group_label>Safety Run-in</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin/pemetrexed or Carboplatin/pemetrexed</intervention_name>
    <description>Patients with PD-L1 TC receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W</description>
    <arm_group_label>Arm A (RMT)</arm_group_label>
    <arm_group_label>Arm B (Placebo)</arm_group_label>
    <arm_group_label>Safety Run-in</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sixteen doses of oral placebo capsules given weekly</description>
    <arm_group_label>Arm B (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the lung that is&#xD;
             unresectable stage IIIB/C or stage IV, does not have an EGFR sensitizing (activating)&#xD;
             mutation or ALK or ROS1 translocation. BRAF, RET, NTRK, MET ex 14 splice site mutation&#xD;
&#xD;
          -  Measurable disease based on RECIST 1.1&#xD;
&#xD;
          -  Tumor sample requirements&#xD;
&#xD;
               -  Mandatory provision of an unstained, archived tumor tissue sample in a quantity&#xD;
                  sufficient to allow for biomarker and genomic analysis. A minimum of 10 unstained&#xD;
                  slides should be available for evaluation.&#xD;
&#xD;
               -  Known PD-L1 TC expression status assayed by Ventana SP263. Patients who have&#xD;
                  known PDL-1 as assayed by PharmDx 22C3 assay may be eligible; however, available&#xD;
                  archival tissue will be used to assay with Ventana SP263 test.&#xD;
&#xD;
          -  Prior chemotherapy or immunotherapy as adjuvant therapy for lung cancer is permitted&#xD;
             as long as it has been &gt;6 months from last dose at the time of enrollment. Local&#xD;
             treatment of isolated lesions, excluding target lesions, for palliative intent is&#xD;
             acceptable (e.g. by local surgery or radiotherapy). Prior systemic therapy for&#xD;
             advanced/metastatic NSCLC makes the patient ineligible for this study.&#xD;
&#xD;
          -  Patients with treated brain metastasis are eligible as long as they have stable&#xD;
             symptoms, are more than 2 weeks from completion of therapy, and do not require more&#xD;
             than 10mg of daily prednisone or equivalent.&#xD;
&#xD;
          -  ECOG Performance status of 0 or 1&#xD;
&#xD;
          -  Body weight of &gt;30 kg&#xD;
&#xD;
          -  Adequate organ function within 14 days of study enrollment defined as:&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count ≥1,500/mcL&#xD;
&#xD;
               -  Platelets ≥ 100,000/mcL&#xD;
&#xD;
               -  Total bilirubin ≤1.5x upper limit of normal (ULN) - this will not apply to&#xD;
                  patients with confirmed Gilbert's syndrome (persistent or recurrent&#xD;
                  hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis&#xD;
                  or hepatic pathology), who will be allowed only in consultation with their&#xD;
                  physician.&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤2.5 x institutional ULN unless liver metastases are&#xD;
                  present, in which case it must be ≤5x ULN&#xD;
&#xD;
               -  Measured creatinine clearance (CL) &gt;40 mL/min or calculated creatinine CL&gt;40&#xD;
                  mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour&#xD;
                  urine collection for determination of creatinine clearance:&#xD;
&#xD;
          -  Expected life expectancy of at least 12 weeks in the opinion of the enrolling&#xD;
             investigator as documented in the medical record&#xD;
&#xD;
          -  Women of childbearing potential and men with partners of child-bearing potential must&#xD;
             agree to use effective contraception for the time of screening to the duration of&#xD;
             treatment and 3 months after the last dose of study drug&#xD;
&#xD;
          -  Provide voluntary written consent prior to the performance of any research related&#xD;
             tests or procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not pregnant or breast feeding. Evidence of post-menopausal status, or negative urine&#xD;
             or serum pregnancy test for female pre-menopausal patients. Women will be considered&#xD;
             postmenopausal if they have amenorrhea for 12 months without an alternative medical&#xD;
             explanation&#xD;
&#xD;
          -  Dysphagia or inability to swallow medications&#xD;
&#xD;
          -  Squamous cell, large cell, or NSCLC NOS (not otherwise specified) histology or mixed&#xD;
             tumors&#xD;
&#xD;
          -  Has untreated brain metastasis or active leptomeningeal carcinomatosis&#xD;
&#xD;
          -  Has a known sensitivity to any component of therapeutic agents used in this study&#xD;
&#xD;
          -  Receipt of any immunotherapy or investigational drug within 4 weeks prior to the first&#xD;
             dose of study drug; and in the case of monoclonal antibodies 6 weeks prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Prior treatment with any other anti-PD-1, or PD-L1, including durvalumab or an&#xD;
             anti-PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory&#xD;
             receptors except as adjuvant therapy for NSCLC so long as it has been greater than six&#xD;
             months since the last treatment&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or&#xD;
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
             prednisone, or an equivalent corticosteroid&#xD;
&#xD;
          -  Recent major surgery within 4 weeks prior to entry into the study (excluding the&#xD;
             placement of vascular access) that would prevent administration of study drug&#xD;
&#xD;
          -  Active or prior documented autoimmune disease within the past 2 years requiring&#xD;
             systemic treatment (i.e. with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs). Patients with vitiligo, Grave's disease, or psoriasis not&#xD;
             requiring systemic treatment (within the past 2 years) are not excluded. Replacement&#xD;
             therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy&#xD;
             for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic&#xD;
             treatment.&#xD;
&#xD;
          -  Active documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)&#xD;
             who require immunosuppression or patients who exceed 10 mg/day of prednisone, or an&#xD;
             equivalent corticosteroid are excluded&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  History of organ transplant that requires therapeutic immunosuppression&#xD;
&#xD;
          -  Taking daily probiotics (patients with last probiotic &gt; 4weeks prior to first dose of&#xD;
             RMT are eligible)&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive) who&#xD;
             are on anti-retroviral treatment for &lt; 6 months and absolute CD4 count&lt;500 (patients&#xD;
             with HIV not meeting these criteria are eligible)&#xD;
&#xD;
          -  Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive&#xD;
             HBsAg, and positive hepatitis B virus quantification assay (patients with history of&#xD;
             Hepatitis B who have seroconversion i.e. Hepatitis B core antibody positive and&#xD;
             Hepatitis B surface antibody positive are eligible). Active Hepatitis C is defined by&#xD;
             a known positive Hep C Ab result and positive quantitative HCV RNA results (Patients&#xD;
             with Hepatitis C who are on anti-viral suppressive therapy and negative quantitative&#xD;
             HCV RNA results are eligible)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active&#xD;
             bleeding diatheses&#xD;
&#xD;
          -  Myocardial infarction or stroke within 3 months prior to enrollment&#xD;
&#xD;
          -  History of systolic or diastolic heart failure with New York Heart Association (NYHA)&#xD;
             class III or IV symptoms (refer to Appendix II)&#xD;
&#xD;
          -  Has active or prior history of (non-infectious) pneumonitis that required steroids or&#xD;
             patients with interstitial lung disease&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements or compromise the ability of the patient to give written informed consent&#xD;
&#xD;
          -  Known history of active tuberculosis. Patients with prior history of latent TB could&#xD;
             be included if they have been treated previously with isoniazid.&#xD;
&#xD;
          -  Patients who are on chronic systemic antibiotic therapy (antibiotics for ≥60&#xD;
             consecutive days within 12 weeks of enrollment). Patients who receive systemic&#xD;
             antibiotics between enrollment and start of RMT are eligible&#xD;
&#xD;
          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within&#xD;
             30 days of receiving RMT&#xD;
&#xD;
          -  History of another primary malignancy (excluding non-melanoma skin cancer) within 5&#xD;
             years prior to starting RMT, except if the patient has undergone potentially curative&#xD;
             therapy with no evidence of disease recurrence for 5 years since initiation of that&#xD;
             therapy&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of the study drug or interpretation of patient safety or study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Kulkarni, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Division of Hematology, Oncology and Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer Center Clinical Trials Office</last_name>
    <phone>612 624 2620</phone>
    <email>ccinfo@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

